Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27280) 27280
Newsletter (1718) 1718
Book Chapter (364) 364
Newspaper Article (66) 66
Dissertation (58) 58
Magazine Article (49) 49
Publication (36) 36
Book / eBook (14) 14
Reference (9) 9
Web Resource (7) 7
Conference Proceeding (6) 6
Book Review (3) 3
Transcript (3) 3
Streaming Video (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (19030) 19030
life sciences & biomedicine (18381) 18381
humans (15944) 15944
male (11450) 11450
animals (9349) 9349
angiotensin (9264) 9264
female (7810) 7810
cardiovascular system & cardiology (6813) 6813
hypertension (6711) 6711
biological and medical sciences (5680) 5680
angiotensin-converting enzyme inhibitors - therapeutic use (5542) 5542
middle aged (5436) 5436
medical sciences (5096) 5096
hypertension - drug therapy (4900) 4900
aged (4691) 4691
rats (4621) 4621
angiotensin ii type 1 receptor blockers - therapeutic use (4387) 4387
angiotensin ii (3874) 3874
peripheral vascular disease (3828) 3828
cardiac & cardiovascular systems (3668) 3668
blood pressure - drug effects (3648) 3648
pharmacology & pharmacy (3455) 3455
antihypertensive agents - therapeutic use (3337) 3337
angiotensin ii type 1 receptor blockers - pharmacology (3221) 3221
adult (3091) 3091
blood pressure (3046) 3046
research (2996) 2996
treatment outcome (2991) 2991
renin-angiotensin system - drug effects (2942) 2942
risk factors (2885) 2885
heart failure (2874) 2874
renin-angiotensin system (2522) 2522
hypertension - physiopathology (2370) 2370
drug therapy (2273) 2273
drug therapy, combination (2239) 2239
cardiology. vascular system (2221) 2221
abridged index medicus (2207) 2207
enzymes (2191) 2191
diabetes (2143) 2143
tetrazoles - therapeutic use (2090) 2090
ace inhibitors (2031) 2031
pharmacology. drug treatments (2012) 2012
cardiovascular system (2010) 2010
analysis (1993) 1993
mice (1949) 1949
angiotensin-converting enzyme inhibitors - pharmacology (1939) 1939
urology & nephrology (1934) 1934
medicine & public health (1913) 1913
angiotensin ii - pharmacology (1885) 1885
angiotensin receptor antagonists (1869) 1869
renin-angiotensin system - physiology (1826) 1826
physiology (1817) 1817
tetrazoles - pharmacology (1799) 1799
heart failure - drug therapy (1776) 1776
care and treatment (1752) 1752
rats, sprague-dawley (1727) 1727
health aspects (1620) 1620
heart (1619) 1619
time factors (1609) 1609
general & internal medicine (1598) 1598
losartan - pharmacology (1554) 1554
cardiology (1522) 1522
medicine, general & internal (1511) 1511
disease models, animal (1503) 1503
adrenergic beta-antagonists - therapeutic use (1495) 1495
dose-response relationship, drug (1452) 1452
angiotensin ii - metabolism (1438) 1438
hypertension - complications (1425) 1425
antihypertensive agents - pharmacology (1421) 1421
physiological aspects (1418) 1418
blood and lymphatic vessels (1415) 1415
mortality (1389) 1389
rodents (1373) 1373
internal medicine (1363) 1363
valsartan (1363) 1363
aged, 80 and over (1356) 1356
renin (1342) 1342
medicine (1338) 1338
receptor, angiotensin, type 1 - metabolism (1336) 1336
angiotensin receptor antagonists - therapeutic use (1325) 1325
benzimidazoles - therapeutic use (1252) 1252
rats, wistar (1250) 1250
angiotensin ii type 1 receptor blockers - administration & dosage (1233) 1233
cardiovascular disease (1213) 1213
angiotensin ii receptor blockers (1207) 1207
enzyme inhibitors (1202) 1202
benzimidazoles - pharmacology (1184) 1184
cardiovascular (1174) 1174
losartan (1173) 1173
endocrinology & metabolism (1164) 1164
angiotensin-converting enzyme inhibitors (1160) 1160
oxidative stress (1152) 1152
cardiovascular diseases (1144) 1144
kidney diseases (1144) 1144
arterial hypertension. arterial hypotension (1139) 1139
calcium channel blockers - therapeutic use (1107) 1107
double-blind method (1106) 1106
prospective studies (1101) 1101
angiotensin-converting enzyme inhibitors - adverse effects (1091) 1091
valine - analogs & derivatives (1083) 1083
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28690) 28690
Japanese (488) 488
German (258) 258
Russian (162) 162
Chinese (137) 137
Spanish (128) 128
French (96) 96
Portuguese (89) 89
Italian (57) 57
Korean (35) 35
Polish (22) 22
Danish (19) 19
Czech (18) 18
Hungarian (14) 14
Swedish (13) 13
Dutch (10) 10
Norwegian (10) 10
Turkish (8) 8
Ukrainian (5) 5
Finnish (4) 4
Croatian (3) 3
Slovak (3) 3
Hebrew (2) 2
Persian (2) 2
Romanian (2) 2
Serbian (2) 2
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
by Patel, Ankit B and Verma, Ashish
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2020, Volume 323, Issue 18, pp. 1769 - 1770
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pandemics | Humans | Hypertension - drug therapy | Peptidyl-Dipeptidase A - drug effects | Virus Internalization | COVID-19 | Lung Injury - enzymology | SARS-CoV-2 | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Pneumonia, Viral - complications | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Peptidyl-Dipeptidase A - metabolism | Betacoronavirus | Coronavirus Infections - complications | Lung Injury - drug therapy | Vasodilation - physiology | Antihypertensive Agents - therapeutic use | SARS Virus - pathogenicity | Antihypertensive Agents - adverse effects | Angiotensin-Converting Enzyme 2 | Animals | Hypertension - complications | Mice | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Hypertension | Pharmacology, Experimental | Comorbidity | Patient outcomes | Angiotensin II receptor blockers | Specialties and specialists | Practice | Research | Standards | Medicine | Physiology, Pathological | Complications and side effects | Physiological aspects | ACE inhibitors | Angiotensin-converting enzyme inhibitors | Enzymes | Receptors | Enzyme inhibitors | Inhibitors | Converting | Peptidyl-dipeptidase A | Angiotensin | Diuretics | Coronaviruses | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study
by Yang, Guang and Tan, Zihu and Zhou, Ling and Yang, Min and Peng, Lang and Liu, Jinjin and Cai, Jingling and Yang, Ru and Han, Junyan and Huang, Yafei and He, Shaobin
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 07/2020, Volume 76, Issue 1, pp. 51 - 58
COVID-19 | coronavirus | angiotensin-converting enzyme inhibitors | angiotensin receptor blocker | inflammation | hypertension | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pandemics | Humans | Middle Aged | Medication Therapy Management - statistics & numerical data | Hypertension - drug therapy | Male | Procalcitonin - analysis | Hypertension - blood | SARS-CoV-2 | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Peptidyl-Dipeptidase A - metabolism | Female | Retrospective Studies | Hypertension - epidemiology | C-Reactive Protein - analysis | Betacoronavirus - isolation & purification | Comorbidity | Pneumonia, Viral - therapy | Treatment Outcome | China - epidemiology | Coronavirus Infections - immunology | Pneumonia, Viral - immunology | Angiotensin-Converting Enzyme 2 | Coronavirus Infections - therapy | Hypertension - virology | Survival Analysis | Aged | Angiotensin Receptor Antagonists - therapeutic use | Virus diseases | Hypertension | Care and treatment | Patient outcomes | Severe acute respiratory syndrome | Angiotensin | Antihypertensive drugs | Epidemiology | ACE inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19
by Zhang, Peng and Zhu, Lihua and Cai, Jingjing and Lei, Fang and Qin, Juan-Juan and Xie, Jing and Liu, Ye-Mao and Zhao, Yan-Ci and Huang, Xuewei and Lin, Lijin and Xia, Meng and Chen, Ming-Ming and Cheng, Xu and Zhang, Xiao and Guo, Deliang and Peng, Yuanyuan and Ji, Yan-Xiao and Chen, Jing and She, Zhi-Gang and Wang, Yibin and Xu, Qingbo and Tan, Renfu and Wang, Haitao and Lin, Jun and Luo, Pengcheng and Fu, Shouzhi and Cai, Hongbin and Ye, Ping and Xiao, Bing and Mao, Weiming and Liu, Liming and Yan, Youqin and Liu, Mingyu and Chen, Manhua and Zhang, Xiao-Jing and Wang, Xinghuan and Touyz, Rhian M and Xia, Jiahong and Zhang, Bing-Hong and Huang, Xiaodong and Yuan, Yufeng and Rohit, Loomba and Liu, Peter P and Li, Hongliang
Circulation research, ISSN 0009-7330, 06/2020, Volume 126, Issue 12, pp. 1671 - 1681
Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Pandemics | Hospital Mortality | Humans | Middle Aged | Hypertension - drug therapy | Male | Inpatients - statistics & numerical data | COVID-19 | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Pneumonia, Viral - complications | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Coronavirus Infections - complications | Hypertension - complications | Female | Aged | Hypertension - epidemiology | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Hypertension | Medical research | Patient outcomes | Analysis | Mortality | Angiotensin | Medicine, Experimental | Antihypertensive drugs | Coronaviruses | ACE inhibitors | Index Medicus | inpatients | Original Research | angiotensin-converting enzyme inhibitor | angiotensin II receptor blocker | 10010 | coronavirus | hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
by Danser, A.H Jan and Epstein, Murray and Batlle, Daniel
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 06/2020, Volume 75, Issue 6, pp. 1382 - 1385
COVID-19 | coronavirus | angiotensin receptor blocker | ACE inhibitor | severe acute respiratory syndrome | Pandemics | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Coronavirus Infections - physiopathology | Peptidyl-Dipeptidase A - physiology | Renin-Angiotensin System - physiology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Pneumonia, Viral - physiopathology | Receptors, Virus - physiology | Pneumonia, Viral - metabolism | Animals | Coronavirus Infections - metabolism | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Betacoronavirus | Renin-Angiotensin System - drug effects | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Receptors, Virus - antagonists & inhibitors | Index Medicus | Reviews | 10010 | 10111
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Abdominal Aortic Aneurysms: Nation-Wide Cohort Study
by Kristensen, Karl Emil and Torp-Pedersen, Christian and Gislason, Gunnar Hilmar and Egfjord, Martin and Rasmussen, Henrik Berg and Hansen, Peter Riis
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 03/2015, Volume 35, Issue 3, pp. 733 - 740
aneurysm | cardiovascular diseases | hypertension | renin-angiotensin system | pharmacoepidemiology | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Aortic Aneurysm, Abdominal - diagnosis | Aortic Aneurysm, Abdominal - drug therapy | Aortic Aneurysm, Abdominal - mortality | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Chi-Square Distribution | Incidence | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Aortic Aneurysm, Abdominal - physiopathology | Aged, 80 and over | Denmark - epidemiology | Female | Registries | Renin-Angiotensin System - drug effects | Vascular Surgical Procedures | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure: The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study
by Matsui, Yoshio and OʼRourke, Michael F and Hoshide, Satoshi and Ishikawa, Joji and Shimada, Kazuyuki and Kario, Kazuomi
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 06/2012, Volume 59, Issue 6, pp. 1132 - 1138
Home blood pressure | Pulse wave velocity | Day-by-day home blood pressure variability | Angiotensin II receptor blocker | Thiazide diuretic | Calcium channel blocker | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiovascular system | Cardiology. Vascular system | Arterial hypertension. Arterial hypotension | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Blood and lymphatic vessels | Antihypertensive agents | Multivariate Analysis | Prospective Studies | Drug Administration Schedule | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Treatment Outcome | Azetidinecarboxylic Acid - analogs & derivatives | Hypertension - physiopathology | Dihydropyridines - therapeutic use | Azetidinecarboxylic Acid - therapeutic use | Diuretics - therapeutic use | Female | Tetrazoles - therapeutic use | Aged | Blood Pressure - drug effects | Blood Pressure Monitoring, Ambulatory - methods | Imidazoles - therapeutic use | Drug Therapy, Combination | Hydrochlorothiazide - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
by Lacro, Ronald V., MD and Dietz, Harry C., MD and Wruck, Lisa M., PhD and Bradley, Timothy J., MD and Colan, Steven D., MD and Devereux, Richard B., MD and Klein, Gloria L., MS and Li, Jennifer S., MD and Minich, L. LuAnn, MD and Paridon, Stephen M., MD and Pearson, Gail D., MD, ScD and Printz, Beth F., MD and Pyeritz, Reed E., MD, PhD and Radojewski, Elizabeth, RN and Roman, Mary J., MD and Saul, J. Philip, MD and Stylianou, Mario P., PhD and Mahony, Lynn, MD and for the Pediatric Heart Network Investigators and Pediat Heart Network Investigators and Pediatric Heart Network Investigators
The American heart journal, ISSN 0002-8703, 2007, Volume 154, Issue 4, pp. 624 - 631
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Atenolol - therapeutic use | Marfan Syndrome - drug therapy | Outcome Assessment (Health Care) | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Losartan - therapeutic use | Adult | Marfan Syndrome - complications | Research Design | Adrenergic beta-Antagonists - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male mice
by Wang, Xingxu and Ye, Yong and Gong, Hui and Wu, Jian and Yuan, Jie and Wang, Shijun and Yin, Peipei and Ding, Zhiwen and Kang, Le and Jiang, Qiu and Zhang, Weijing and Li, Yang and Ge, Junbo and Zou, Yunzeng
Journal of molecular and cellular cardiology, ISSN 0022-2828, 08/2016, Volume 97, pp. 180 - 190
Heart failure | Angiotensin II type 1-receptor blockers | Cardiac hypertrophy | Pressure overload | Mechanical stretch | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cell Biology | Angiotensin II - genetics | Receptors, G-Protein-Coupled - metabolism | Cardiomegaly - etiology | Cardiomegaly - pathology | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | RNA, Small Interfering - chemistry | Myocardium - metabolism | Peptidyl-Dipeptidase A - metabolism | Blood Pressure - drug effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Disease Models, Animal | Proto-Oncogene Proteins - metabolism | Echocardiography | Angiotensin II - metabolism | Cardiomegaly - physiopathology | Angiotensin II - deficiency | Hypertension - physiopathology | Mice, Knockout | Animals | Myocytes, Cardiac - drug effects | Signal Transduction - drug effects | Receptor, Angiotensin, Type 1 - metabolism | Hypertension - complications | Myocytes, Cardiac - metabolism | Hemodynamics - drug effects | Mice | Ventricular Remodeling - drug effects | Heart | Analysis | Angiotensin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective
by South, Andrew M and Brady, Tammy M and Flynn, Joseph T
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 07/2020, Volume 76, Issue 1, pp. 16 - 22
Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pandemics | Comorbidity | Humans | Angiotensin Receptor Antagonists - pharmacology | Hypertension - drug therapy | Renin-Angiotensin System - physiology | Hypertension - metabolism | COVID-19 | Pneumonia, Viral - metabolism | Angiotensin-Converting Enzyme 2 | SARS-CoV-2 | Coronavirus Infections - metabolism | Coronavirus Infections - epidemiology | Coronavirus Infections - virology | Pneumonia, Viral - epidemiology | Betacoronavirus - physiology | Peptidyl-Dipeptidase A - metabolism | Renin-Angiotensin System - drug effects | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Hypertension - epidemiology | Child | Pneumonia, Viral - virology | Hypertension | Pediatrics | Medical colleges | Angiotensin | Kidney diseases | Children | Coronaviruses | Epidemiology | ACE inhibitors | Risk factors | Diseases | Cardiovascular agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus: A Meta-analysis
by Cheng, Jun and Zhang, Wen and Zhang, Xiaohui and Han, Fei and Li, Xiayu and He, Xuelin and Li, Qun and Chen, Jianghua
JAMA internal medicine, ISSN 2168-6106, 05/2014, Volume 174, Issue 5, pp. 773 - 785
General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Regression Analysis | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Diabetes Mellitus - drug therapy | Cardiovascular Diseases - mortality | Treatment Outcome | Angiotensin Receptor Antagonists - therapeutic use | Cause of Death | Diabetes Complications - prevention & control | Randomized Controlled Trials as Topic | Complications and side effects | Care and treatment | Usage | Mortality | Angiotensin II receptor blockers | Influence | Diabetes | Cardiovascular diseases | ACE inhibitors | Risk factors | Meta-analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Use of β-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study
by Gitte Vrelits Sørensen and Patricia A. Ganz and Steven W. Cole and Lars A. Pedersen and Henrik Toft Sørensen and Deirdre P. Cronin-Fenton and Jens Peter Garne and Peer M. Christiansen and Timothy L. Lash and Thomas P. Ahern
Journal of clinical oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 18, pp. 2265 - 2272
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Risk Assessment - methods | Prospective Studies | Humans | Middle Aged | Risk Factors | Neoplasm Recurrence, Local | Proportional Hazards Models | Breast Neoplasms - drug therapy | Risk Assessment - statistics & numerical data | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Breast Neoplasms - pathology | Registries - statistics & numerical data | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Aged, 80 and over | Denmark | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Aged | Breast Neoplasms - chemically induced | Angiotensin Receptor Antagonists - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Index Medicus | Bc1 | ORIGINAL REPORTS | Bc8
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - A randomized study
by Takahashi, Akihiko and Takase, Hiroyuki and Toriyama, Takayuki and Sugiura, Tomonori and Kurita, Yutaka and Ueda, Ryuzo and Dohi, Yasuaki
Nephrology, dialysis, transplantation, ISSN 0931-0509, 09/2006, Volume 21, Issue 9, pp. 2507 - 2512
Brain natriuretic peptide | Cardiovascular disease | Angiotensin receptor antagonists | Randomized trail | Congestive heart failure | Cardiovascular mortality | Transplantation | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Diabetes. Impaired glucose tolerance | Emergency and intensive care: renal failure. Dialysis management | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Nephropathies. Renovascular diseases. Renal failure | Renal failure | Nephrology. Urinary tract diseases | Biological and medical sciences | Endocrinopathies | Intensive care medicine | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Associated diseases and complications | Cardiovascular Diseases - etiology | Japan - epidemiology | Prospective Studies | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Proportional Hazards Models | Male | Survival Rate | Treatment Outcome | Incidence | Kidney Failure, Chronic - therapy | Renal Dialysis - adverse effects | Cardiovascular Diseases - epidemiology | Female | Tetrazoles - therapeutic use | Benzimidazoles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights